Spyre Therapeutics
SYRE
SYRE
23 hedge funds and large institutions have $38.5M invested in Spyre Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
23
Holders Change
-3
Holders Change %
-11.54%
% of All Funds
0.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
5
Reduced
5
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$814K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$617K |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$294K |
| 4 |
Renaissance Technologies
New York
|
+$270K |
| 5 |
Bank of New York Mellon
New York
|
+$157K |
Top Sellers
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$1.6M |
| 2 |
VMI
VHCP Management II
New York
|
-$1.52M |
| 3 |
PA
Perceptive Advisors
New York
|
-$722K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$275K |
| 5 |
SCM
Sio Capital Management
New York
|
-$138K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
SIM
26
Spark Investment Management
New York
| – | -$52K | -480 | Closed |
|
27
Goldman Sachs
New York
| – | -$45K | -415 | Closed |
|
28
Acadian Asset Management
Boston,
Massachusetts
| – | -$2K | -19 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$1K | -8 | Closed |
|